🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
7.04
-0.20 (-2.76%)
At close: Nov 20, 2026, 4:00 PM EST
7.03
-0.01 (-0.14%)
After-hours: Nov 20, 2026, 7:30 PM EST

Evommune Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
-1375
Revenue Growth
-85.71%40.00%-
Gross Profit
-1375
Selling, General & Admin
33.2120.0312.7710.85
Research & Development
88.6974.0464.2432
Operating Expenses
121.8994.0777.0142.85
Operating Income
-121.89-81.07-70.01-37.85
Interest Expense
--0.01-0.03-0.06
Interest & Investment Income
8.863.323.243.86
Other Non Operating Income (Expenses)
-0.048.89-0-0
Pretax Income
-113.07-68.87-66.81-34.05
Net Income
-113.07-68.87-66.81-34.05
Preferred Dividends & Other Adjustments
--1.5-
Net Income to Common
-113.07-68.87-68.31-34.05
Net Income Growth
----
Shares Outstanding (Basic)
32621
Shares Outstanding (Diluted)
32621
Shares Change
1950.51%306.86%20.35%-
EPS (Basic)
-3.59-11.22-45.29-27.17
EPS (Diluted)
-3.59-11.22-45.29-27.17
EPS Growth
----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23
Free Cash Flow
-91-76.68-58.28-30.09
Free Cash Flow Per Share
-2.89-12.49-38.64-24.01
Gross Margin
-100.00%100.00%100.00%
Operating Margin
--623.62%-1000.19%-757.00%
Profit Margin
--529.77%-975.83%-681.06%
Free Cash Flow Margin
--589.82%-832.61%-601.76%
EBITDA
-120.13-79.68-68.73-36.85
D&A For EBITDA
1.771.391.291
EBIT
-121.89-81.07-70.01-37.85
Revenue as Reported
-1375
SEC Filings: 10-K · 10-Q